Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Interaction Potential Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

NCT00930865
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bumetanide, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants

NCT04545944
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan, Midazolam
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach

NCT06693960
View directory record Official record
Conditions
Interaction
Interventions
Oregano, Drug cocktail
Dietary Supplement · Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen

NCT03324685
View directory record Official record
Conditions
Drug Interactions
Interventions
BIIB074, OC (ethinyl estradiol and levonorgestrel)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants

NCT06092931
View directory record Official record
Conditions
Healthy Participants
Interventions
DC-806, Midazolam, Repaglinide, Digoxin, Rosuvastatin
Drug
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

TAK-875 Glimepiride Drug-Interaction Study

NCT01496443
View directory record Official record
Conditions
Pharmacokinetics
Interventions
TAK-875 and Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 68 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Results available

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

NCT03291288
View directory record Official record
Conditions
Drug Interaction Potential
Interventions
Tolbutamide, Midazolam, Pexidartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

NCT06945276
View directory record Official record
Conditions
COVID-19
Interventions
ALG-097558, Dabigatran, Itraconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

NCT05684289
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986278, Sildenafil, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
35 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

Allopurinol Combination Study

NCT01001338
View directory record Official record
Conditions
Gout
Interventions
RDEA594, Placebo, Allopurinol
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

NCT04933682
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, Fluconazole, Rifampin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women

NCT07542847
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OPC-167832, Itraconazole, Carbamazepine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

NCT05852769
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986196, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, Pravastatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

NCT00000941
View directory record Official record
Conditions
HIV Infections
Interventions
Pravastatin sodium, Simvastatin, Atorvastatin calcium, Ritonavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2002
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Results available

Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study

NCT02563769
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Addiction, Cocaine Abuse, Cocaine-Related Disorders
Interventions
Clavulanic acid, Intravenous cocaine, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects

NCT00666796
View directory record Official record
Conditions
Insomnia
Interventions
Placebo ethanol, Ethanol, Placebo, Gabapentin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)

NCT01918176
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib alone, Palbociclib + Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With a Potential Alzheimer's Disease Compound

NCT00726726
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan), BMS-708163, BMS-708163 + Cooperstown Cocktail
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2008 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Potential of Mavorixafor

NCT06914869
View directory record Official record
Conditions
Healthy Participants
Interventions
Mavorixafor, Carbamazepine, Efavirenz
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

NCT06071442
View directory record Official record
Conditions
Healthy Participants
Interventions
Vemircopan, Rosuvastatin, Metformin, Levonorgestrel / Ethinyl Estradiol, Carbamazepine
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

MAD Study of IA-14069

NCT05533372
View directory record Official record
Conditions
Healthy, Rheumatoid Arthritis
Interventions
IA-14069, Placebo, Methotrexate
Drug
Lead sponsor
ILAb Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants

NCT07629999
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986533, Famotidine, Placebo, Dabigatran Etexilate, Rosuvastatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

Opioid Drug Interaction Study

NCT06757140
View directory record Official record
Conditions
Drug Interactions, Drug Kinetics
Interventions
Alprazolam, Oxycodone, Placebo
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Results available

SXC-2023 Cocaine Interaction Study

NCT06343532
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
SXC-2023, SXC-2023 Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 59 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 22, 2026, 10:53 AM EDT